High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease
- 28 October 2010
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 116 (17) , 3180-3184
Abstract
Most patients diagnosed with primary chronic cold agglutinin disease (CAD) have a clonal lymphoproliferative bone marrow disorder. Treatment with rituximab is the only well-documented effective therapy, leading to 45%-60% partial responses (PR). Complete responses (CR) are rare, and median response duration is only 11 months. In a prospective multicenter trial, 29 patients received rituximab 375 mg/m2 on days 1, 29, 57 and 85; and fludarabine orally, 40 mg/m2 on days 1-5, 29-34, 57-61 and 85-89. Twenty-two patients (76%) responded, 6 (21%) achieving CR and 16 (55%) PR. Among 10 patients nonresponsive to rituximab monotherapy, 1 achieved CR and 6 PR. Median increase in hemoglobin level was 3.1 g/dL among the responders and 4.0 g/dL in those who achieved CR. Lower quartile of response duration was not reached after 33 months. Estimated median response duration was more than 66 months. Grade 3-4 hematologic toxicity occurred in 12 patients (41%). In conclusion, fludarabine and rituximab combination therapy is very efficient in patients with CAD. Toxicity may be a concern, and benefits should be carefully weighed against risks in very old and comorbid patients. It remains to be established whether the combination should be first-line or an efficient second-line therapy in CAD patients requiring treatment. This study is registered at http://www.clinicaltrials.gov as NCT00373594.Keywords
This publication has 24 references indexed in Scilit:
- Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodiesCurrent Opinion in Immunology, 2008
- Rituximab for the treatment of autoimmune cytopeniasHaematologica, 2007
- Primary chronic cold agglutinin disease: An update on pathogenesis, clinical features and therapyHematology, 2007
- Anti-CD20 Therapy and Autoimmune Disease: Therapeutic opportunities and evolving insightsFrontiers in Bioscience-Landmark, 2007
- Update on treatment recommendations from the Third International Workshop on Waldenstrom's MacroglobulinemiaBlood, 2006
- Cold Hemolytic SyndromeHematology-American Society Hematology Education Program, 2006
- Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular LymphomaJournal of Clinical Oncology, 2005
- Fludarabine in Waldenstrom's macroglobulinemiaSeminars in Oncology, 2003
- Failure of interferon‐α‐2b therapy in chronic cold agglutinin diseaseEuropean Journal of Haematology, 1994
- Exclusive Occurrence of k Chains in Isolated Cold HaemagglutininsScandinavian Journal of Haematology, 1965